Your search history is turned on.
Date: December 29, 2023 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
Complete_with_DocuSign_Cognetivity_-_Form_52 (2).pdf Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Thomas Sawyer, Chief Financial Officer of Cognetivity Neurosciences Ltd., certify the following: 1. Review: Cognetivity Neurosciences Ltd October 31, 2023. 2. No misrepresentations: Based on my knowledge, having exercised r...
Complete_with_DocuSign_Cognetivity_-_Form_52 (3).pdf Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Sina Habibi, Chief Executive Officer of Cognetivity Neurosciences Ltd., certify the following: 1. Review: Cognetivity Neurosciences Ltd October 31, 2023. 2. No misrepresentations: Based on my knowledge, having exercised rea...
Microsoft Word - CNL - MDA - 2023 10 31_V2_Clean.docx COGNETIVITY NEUROSCIENCES LTD. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS For the Nine Months ended October 31, 2023 GENERAL This Managements Discussion and Analysis (MD&A) has been prepared by management as of December 29, 2023, and it presents ...
Microsoft Word - CNL - FS - 2023 10 31.docx COGNETIVITY NEUROSCIENCES LTD. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS For the nine-month periods ended October 31, 2023 and 2022 (UNAUDITED, EXPRESSED IN CANADIAN DOLLAR) The accompanying notes are integral to these interim condensed consolidated finan...
Date: November 24, 2023 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
Microsoft Word - Class C share redemption Nov 2023.docx Class C Preferred Shares - Redemption Vancouver, British Columbia, November 24, 2023 - Cognetivity Neurosciences Ltd. ("the Company" or "Cognetivity") (CSE: CGN, OTCQB: CGNSF, FWB.1UB) reports today that it has received notice of redemption of 14,415,270 Class C shares representing a total redemption amount...
Date: October 24, 2023 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
CognICA(TM) Shown to Save Tens of Millions of Dollars in Healthcare Costs Annually and Improve Patient Outcomes in the UK National Health Service Latest Peer-Reviewed Study Published in Frontiers in Public Health Highlights Cost-Efficiency and Improved Clinical Outcomes from Using Cognetivity's Proprietary CognICA(TM) Technology, Showing Savings of Over 40 Million Per Year Compared with Tradition...
Date: October 11, 2023 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
Cognetivity Neurosciences and UC Health Partner to Improve Early Detection of Cognitive Impairment in USA Collaboration With Highly Rated Healthcare Provider Opens US Healthcare Market for Brain Health for AI Powered CognICA, Enabling Patient Access to Latest Alzheimer's Drugs Vancouver, British Columbia--(Newsfile Corp. - October 11, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTC Pink: CG...
Date: October 3, 2023 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
Cognetivity Neurosciences Announces Commercial Agreement with Mediclinic to Provide Cognitive Assessment to Over 50s Program Designed to Identify Age-Related Brain Health Issues at an Early Stage, Allowing Effective Provision of Coordinated Care Vancouver, British Columbia--(Newsfile Corp. - October 3, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTC Pink: CGNSF) (FSE: 1UB) ("the Company" or...
Date: September 29, 2023 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
Microsoft Word - CGN - post-IFRS 52-109FV2 [F] (CEO) - F2024-Q2.doc 1 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Sina Habibi, Chief Executive Officer of Cognetivity Neurosciences Ltd, certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) ...
Microsoft Word - CGN - post-IFRS 52-109FV2 [F] (CFO) - F2024-Q2.doc 1 Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Thomas Sawyer, Chief Financial Officer Cognetivity Neurosciences Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) ...